Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
4.200
+0.360 (9.38%)
At close: Apr 28, 2026, 4:00 PM EDT
4.120
-0.080 (-1.90%)
After-hours: Apr 28, 2026, 5:47 PM EDT
IMDX Employees
As of December 31, 2025, Insight Molecular Diagnostics had 58 total employees, including 55 full-time and 3 part-time employees. The number of employees increased by 9 or 18.37% compared to the previous year.
Employees
58
Change (1Y)
9
Growth (1Y)
18.37%
Revenue / Employee
$69,914
Profits / Employee
-$865,897
Market Cap
135.11M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Myriad Genetics | 2,700 |
| Fulgent Genetics | 1,315 |
| Castle Biosciences | 883 |
| Burning Rock Biotech | 674 |
| FONAR | 535 |
| MDxHealth | 364 |
| Biodesix | 334 |
| Prenetics Global | 285 |
IMDX News
- 13 days ago - Insight Molecular Diagnostics Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 14 days ago - Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay - GlobeNewsWire
- 4 weeks ago - Insight Molecular Diagnostics Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results - GlobeNewsWire
- 5 weeks ago - iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Score - GlobeNewsWire
- 2 months ago - Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission - GlobeNewsWire
- 2 months ago - iMDx Announces $26.0 Million Registered Direct Offering - GlobeNewsWire